IL154006A0 - Method for treating unstable angina pectoris - Google Patents

Method for treating unstable angina pectoris

Info

Publication number
IL154006A0
IL154006A0 IL15400601A IL15400601A IL154006A0 IL 154006 A0 IL154006 A0 IL 154006A0 IL 15400601 A IL15400601 A IL 15400601A IL 15400601 A IL15400601 A IL 15400601A IL 154006 A0 IL154006 A0 IL 154006A0
Authority
IL
Israel
Prior art keywords
angina pectoris
unstable angina
treating unstable
treating
hypercholesterolaemia
Prior art date
Application number
IL15400601A
Other languages
English (en)
Original Assignee
Zlb Bioplasma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zlb Bioplasma Ag filed Critical Zlb Bioplasma Ag
Publication of IL154006A0 publication Critical patent/IL154006A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Supports For Pipes And Cables (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL15400601A 2000-07-20 2001-07-20 Method for treating unstable angina pectoris IL154006A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10035352A DE10035352A1 (de) 2000-07-20 2000-07-20 Verfahren zur Behandlung von instabiler Angina pectoris
PCT/EP2001/008425 WO2002007753A2 (de) 2000-07-20 2001-07-20 Verfahren zur behandlung von instabiler angina pectoris

Publications (1)

Publication Number Publication Date
IL154006A0 true IL154006A0 (en) 2003-07-31

Family

ID=7649620

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15400601A IL154006A0 (en) 2000-07-20 2001-07-20 Method for treating unstable angina pectoris
IL154006A IL154006A (en) 2000-07-20 2003-01-16 Use of High Concentration Lipoprotein (HDL) Restored to Manufacture Compounds for Vascular Disease for Acute Improvement of Endothelial Activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154006A IL154006A (en) 2000-07-20 2003-01-16 Use of High Concentration Lipoprotein (HDL) Restored to Manufacture Compounds for Vascular Disease for Acute Improvement of Endothelial Activity

Country Status (17)

Country Link
US (1) US7053049B2 (hu)
EP (1) EP1303294B1 (hu)
JP (1) JP4928047B2 (hu)
KR (2) KR100864079B1 (hu)
AT (1) ATE333887T1 (hu)
AU (2) AU8200401A (hu)
CA (1) CA2418238C (hu)
DE (2) DE10035352A1 (hu)
DK (1) DK1303294T3 (hu)
ES (1) ES2266234T3 (hu)
HU (1) HU230151B1 (hu)
IL (2) IL154006A0 (hu)
NO (1) NO329848B1 (hu)
NZ (1) NZ523784A (hu)
PL (1) PL204406B1 (hu)
WO (1) WO2002007753A2 (hu)
ZA (1) ZA200300509B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US7956035B2 (en) * 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
CA2780482A1 (en) 2008-11-17 2010-05-10 Anil K. Sood Hdl particles for delivery of nucleic acids
US9268023B2 (en) 2012-09-25 2016-02-23 Hewlett-Packard Development Company, L.P. Drop detection
ITMI20131300A1 (it) * 2013-08-01 2015-02-02 Nobil Bio Ricerche Srl Composizione per il riempimento di difetti ossei e parodontali
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
GB2603950A (en) 2021-02-22 2022-08-24 Reckitt & Colman Overseas Hygiene Home Ltd Effervescent germicidal compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
CA1335077C (en) * 1988-02-08 1995-04-04 Henri Isliker Process for the manufacture of apolipoproteins from human blood plasma or serum
EP0543417A1 (en) * 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
JPH10218861A (ja) * 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AU777788B2 (en) * 1999-11-26 2004-10-28 Heart Research Institute Limited, The Oxidized apolipoproteins and methods of use
AUPQ429399A0 (en) * 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Also Published As

Publication number Publication date
DE50110552D1 (de) 2006-09-07
NZ523784A (en) 2004-06-25
CA2418238C (en) 2012-06-05
EP1303294A2 (de) 2003-04-23
KR20030026980A (ko) 2003-04-03
EP1303294B1 (de) 2006-07-26
PL204406B1 (pl) 2010-01-29
KR20070108955A (ko) 2007-11-13
HUP0300730A2 (hu) 2003-12-29
AU2001282004B2 (en) 2006-02-02
HUP0300730A3 (en) 2010-07-28
CA2418238A1 (en) 2003-01-16
DK1303294T3 (da) 2006-10-30
US20040014654A1 (en) 2004-01-22
JP4928047B2 (ja) 2012-05-09
AU8200401A (en) 2002-02-05
NO329848B1 (no) 2011-01-10
JP2004504355A (ja) 2004-02-12
WO2002007753A2 (de) 2002-01-31
ATE333887T1 (de) 2006-08-15
DE10035352A1 (de) 2002-01-31
ZA200300509B (en) 2004-02-17
ES2266234T3 (es) 2007-03-01
HU230151B1 (hu) 2015-09-28
WO2002007753A3 (de) 2003-02-13
PL366395A1 (en) 2005-01-24
KR100864079B1 (ko) 2008-10-16
IL154006A (en) 2010-05-31
NO20030137D0 (no) 2003-01-10
NO20030137L (no) 2003-01-10
US7053049B2 (en) 2006-05-30

Similar Documents

Publication Publication Date Title
NO20034056D0 (no) Proliferative sykdommer
AP2003002890A0 (en) Therapeutic combinations for cardiovascular and inflammatory indications.
BR9913564A (pt) Tratamento de angiopatias microvasculares
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
MXPA05012755A (es) Nitrooxiderivados de fluvastatina, pravastatina, cerivastatina, atorvastatina y rosuvastatina como agentes reductores del colesterol con mejor actividad anti-inflamatoria, anti-trombotica y anti-plaquetaria.
WO2003026643A3 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
IL153359A0 (en) Peptides, compositions and methods for the treatment of burkholderia cepacia
MXPA03004517A (es) Metodos que emplean y composiciones que contienen fosfolipidos oxidados definidos para la prevencion y tratamiento de la arteriosclerosis.
IL154006A0 (en) Method for treating unstable angina pectoris
WO2002005848A3 (en) Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
SE9603725D0 (sv) New teatment
MY118381A (en) Statin-carboxyalkylether combinations
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
WO2004009029A3 (en) Compositions and methods for treating and preventing infection
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
AU2001291308A1 (en) Methods and compositions for treating nail fungus
AU2001262378A1 (en) Method for treating cryptorchidism
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
WO2001062792A3 (en) Cancer treatment and prognosis involving hes-1 protein
LT2002131A (en) New use of fir oil for cosmetic
AU2001281747A1 (en) Composition and method for the treatment or prevention of hiv infection
UA32314A (uk) Спосіб лікування некротичного панкреатиту

Legal Events

Date Code Title Description
HC Change of name of proprietor(s)

Owner name: CSL BEHRING AG

Free format text: FORMER NAME:ZLB BEHRING AG